AUPH Aurinia Pharmaceuticals Inc
Mergers ·
Aurinia said on May 11, 2026 that it completed its acquisition of Kezar Life Sciences. Holders received $6.955 in cash plus one contingent value right per share, after a tender offer in which 5,927,580 Kezar shares, about 80.24% of those outstanding, were validly tendered.
An Aurinia subsidiary will buy Kezar Life Sciences for $6.955 in cash per share plus a CVR, but the offer depends on Kezar holding at least $50.0 million of net cash at closing. The deal is expected to close in the second quarter of 2026.
Aurinia Pharmaceuticals is a biopharmaceutical company focused on therapies for people living with autoimmune diseases with high unmet medical needs. Its marketed product, LUPKYNIS (voclosporin), was introduced in January 2021 as the first FDA-approved oral therapy for adult patients with active lupus nephritis (LN). Aurinia sells LUPKYNIS in the U.S. through two specialty pharmacies and a specialty distributor, and reported net product sales of $271.3 million for 2025, up 25% from $216.2 million in 2024. Its collaboration partner Otsuka has rights to oral voclosporin in Japan, the European Union, the United Kingdom, Switzerland and other listed territories, where Otsuka has obtained regulatory approval for LUPKYNIS. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for potential treatment of autoimmune diseases. The text says over 200,000 people in the U.S. are estimated to have systemic lupus erythematosus (SLE), and that 20% to 60% of them develop lupus nephritis. Lonza is its contract manufacturing partner for voclosporin.
| Product or program | What it is | Stage |
|---|---|---|
| LUPKYNIS | Oral voclosporin for active lupus nephritis in adults | FDA-approved |
| aritinercept | Dual BAFF and APRIL inhibitor for autoimmune diseases | developing |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $283.1 million | $235.1 million |
| Research and development | $32.5 million | $20.8 million |
| Net income (loss) | $287.2 million | $5.8 million |
| Cash from operations | $135.7 million | $44.4 million |
| Cash and equivalents | $80.2 million | $83.4 million |
Our latest story on this, dated May 11, 2026: "Aurinia completes Kezar Life Sciences acquisition after tender offer at $6.955 per share plus CVR". The story links the filing or release it is based on. Read the story.
Aurinia Pharmaceuticals Inc trades under the ticker AUPH on NASDAQ.
Aurinia Pharmaceuticals Inc is listed on NASDAQ. Our directory also records these other listings: GETTEX:IKAP; LS:A1W7D4.
The SEC Central Index Key (CIK) for Aurinia Pharmaceuticals Inc is 1600620. Its filings are on SEC EDGAR.
133,051,168 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Aurinia Pharmaceuticals Inc under Canada.
Our directory classifies Aurinia Pharmaceuticals Inc as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Aurinia Pharmaceuticals Inc is CA05156V1022.
aibio.space lists Aurinia Pharmaceuticals Inc among 2,820 public biotech companies and publishes its news here as stories appear.
Aurinia Pharmaceuticals is a biopharmaceutical company focused on therapies for people living with autoimmune diseases with high unmet medical needs. Its marketed product, LUPKYNIS (voclosporin), was introduced in January 2021 as the first FDA-approved oral therapy for adult patients with active lupus nephritis (LN).
LUPKYNIS: Oral voclosporin for active lupus nephritis in adults Stage: FDA-approved.
aritinercept: Dual BAFF and APRIL inhibitor for autoimmune diseases Stage: developing.
$283.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Aurinia Pharmaceuticals Inc reported net income of $287.2 million for the fiscal year ended Dec 31, 2025, and generated $135.7 million of cash from operations, per its annual report to the SEC.
$32.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio